The Outcomes of Small-Molecule Kinase Inhibitors and the Role of ROCK2 as a Molecular Target for the Treatment of Alzheimer's Disease

被引:2
作者
Tolomeu, Heber Victor [1 ,2 ]
Manssour Fraga, Carlos Alberto [1 ,2 ]
机构
[1] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Lab Avaliacao & Sintese Substancias Bioat LASSBio, BR-21941902 Rio De Janeiro, RJ, Brazil
[2] Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Programa Posgrad Farmacol & Quim Med, BR-21941902 Rio De Janeiro, RJ, Brazil
关键词
Alzheimer's disease; Neurodegenerative diseases; Kinase inhibitors; Rho kinase 2; ROCK2; inhibitor; RHO-ASSOCIATED KINASE; PROTEIN-KINASE; SERINE/THREONINE KINASE; INTERACTION MAP; AMYLOID-BETA; ROK-ALPHA; BINDING; MECHANISM; RECOGNITION; DOMAIN;
D O I
10.2174/1871527320666210820092220
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Alzheimer's disease is rapidly becoming a major threat to public health, with an increasing number of individuals affected as the world's population ages. In this sense, stud-ies have been carried out aiming at the identification of new small-molecule kinase inhibitors useful for the treatment of Alzheimer's disease. Objective: In the present study, we investigated the compounds developed as inhibitors of different protein kinases associated with the pathogenesis of Alzheimer's disease. Methods: The applied methodology was the use of the Clarivate Analytics Integrity and ClinicalTri-als.com databases. Moreover, we highlight ROCK2 as a promising target despite being little studied for this purpose. A careful structure-activity relationship analysis of the ROCK2 inhibitors was per -formed to identify important structural features and fragments for the interaction with the kinase ac-tive site, aiming to rationally design novel potent and selective inhibitors. Results: We were able to notice some structural characteristics that could serve as the basis to better guide the rational design of new ROCK2 inhibitors as well as some more in-depth characteristics regarding the topology of the active site of both isoforms of these enzymes, thereby identifying dif-ferences that could lead to planning more selective compounds. Conclusion: We hope that this work can be useful to update researchers working in this area, ena-bling the emergence of new ideas and a greater direction of efforts for designing new ROCK2 inhib-itors to identify new therapeutic alternatives for Alzheimer's disease.
引用
收藏
页码:188 / 205
页数:18
相关论文
共 50 条
  • [21] Recent advances of small molecule JNK3 inhibitors for Alzheimer?s disease
    Qin, Pengxia
    Ran, Yingying
    Liu, Yujing
    Wei, Chao
    Luan, Xiaoyi
    Niu, Haoqian
    Peng, Jie
    Sun, Jie
    Wu, Jingde
    BIOORGANIC CHEMISTRY, 2022, 128
  • [22] Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease
    Kazim, Syed Faraz
    Iqbal, Khalid
    MOLECULAR NEURODEGENERATION, 2016, 11
  • [23] Therapeutic Effects of Natural Compounds and Small Molecule Inhibitors Targeting Endoplasmic Reticulum Stress in Alzheimer's Disease
    Gao, Xun
    Xu, Yuanyuan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [24] Natural Small-molecule Compounds Prevent Immune Imbalance via Regulating Microglia in Alzheimer's Disease
    Cao Yan-Zi
    Wang Qin-Wen
    Yang Meng-Jie
    Bao Rong-Rong
    Xu Shu-Jun
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2020, 47 (08) : 712 - 728
  • [25] Role of Natural Compounds and Target Enzymes in the Treatment of Alzheimer's Disease
    Wang, Shanshan
    Kong, Xianbo
    Chen, Zhangjing
    Wang, Guopin
    Zhang, Juan
    Wang, Jing
    MOLECULES, 2022, 27 (13):
  • [26] Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy
    Wang, Huiping
    Jin, Wenke
    Li, Zixiang
    Guo, Chuanxin
    Zhang, Lan
    Fu, Leilei
    DRUG DISCOVERY TODAY, 2024, 29 (10)
  • [27] Repurposing of Kinase Inhibitors to Target c-Abl as Potential Therapeutics for Alzheimer's Disease
    Zhu, Qingzhang
    Chen, Jianchun
    Wu, Xi
    Jin, Xiaoping
    Ruan, Bing
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2014, 9 (04) : 331 - 340
  • [28] Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease
    Leshchiner, Elizaveta S.
    Rush, Jason S.
    Durney, Michael A.
    Cao, Zhifang
    Dancik, Vlado
    Chittick, Benjamin
    Wu, Huixian
    Petrone, Adam
    Bittker, Joshua A.
    Phillips, Andrew
    Perez, Jose R.
    Shamji, Alykhan F.
    Kaushik, Virendar K.
    Daly, Mark J.
    Graham, Daniel B.
    Schreiber, Stuart L.
    Xavier, Ramnik J.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (43) : 11392 - 11397
  • [29] Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy
    Sheng, Li
    Bhalla, Rajiv
    NEUROCHEMICAL RESEARCH, 2024, 49 (09) : 2273 - 2302
  • [30] Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease
    Nie, Qin
    Du, Xiao-guang
    Geng, Mei-yu
    ACTA PHARMACOLOGICA SINICA, 2011, 32 (05) : 545 - 551